Drug manufacture
Our multi-disciplinary teams are developing technologies for the identification and manufacture of medicines, from precision medicines, to scale up of reactors. Our technologies aim to reduce costs, improve speed of manufacture, improve patient benefit and increase sustainability of manufacture.
Personalised medicine
We are investigating a range of new technologies that enable increased flexibility in medicine manufacture that can deliver stratified or so called precision medicines for small groups of patients.
Future Targeted Healthcare Manufacturing Hub
The University of Nottingham is part of the £20m EPSRC Future Targeted Healthcare Manufacturing Hub (led by UCL)
Accelerating discovery of new medicines
A new £12 million partnership between the Universities of Nottingham and Strathclyde and pharmaceutical company GSK will accelerate research into the discovery of new medicines.
The five-year ESPRC funded programme will see the partners deliver a new suite of methods and approaches to tackle some of the major challenges in the discovery, development, and manufacture of medicines.
The research programme aims to enable the production of transformative medicines at lower costs with reduced waste production and shorter time for manufacture.
Focus areas include:
- Use of Artificial Intelligence and machine learning to identify next generation medicines (Jonathan Hirst, Professor of Computational Chemistry)
- Next generation catalysis and synthesis
- Sustainable processes for scale-up (Peter Licence, Professor of Chemistry)
- Digital manufacture (Ricky Wildman, Professor of Multiphase Flow and Mechanics)
Details of the grant
Press release on the award
Design of reactors to manufacture medicines
We are using continuous photochemistry and electrochemistry with the aim of transforming the manufacture of pharmaceuticals and other chemicals, making it more sustainable.